RETRACTED: Downregulation of microRNA-586 Inhibits Proliferation, Invasion and Metastasis and Promotes Apoptosis in Human Osteosarcoma U2-OS Cell Line (Retracted article. See vol. 161, pg. 478, 2021)

被引:14
作者
Yang, Lei [1 ]
Liu, Zong-Ming [2 ]
Rao, Yan-Wei [3 ]
Cui, Shao-Qian [1 ]
Wang, Huan [1 ]
Jia, Xiao-Jing [4 ]
机构
[1] Jilin Univ, Dept Radiol, Jilin Canc Hosp, Changchun 130041, Peoples R China
[2] Jilin Univ, Dept Anesthesiol, Jilin Canc Hosp, Changchun 130041, Peoples R China
[3] Jilin Univ, Dept Emergency & Crit Med, Jilin Prov Peoples Hosp, Changchun 130041, Peoples R China
[4] Jilin Univ, Dept Radiotherapy, Hosp 2, Changchun 130041, Peoples R China
关键词
Apoptosis; Invasion; Lentivirus; Metastasis; MicroRNA-586; Osteosarcoma; Proliferation; EXPRESSION PROFILE; GROWTH-FACTOR; MIRNA; PROGNOSIS; THERAPY; PATHWAY;
D O I
10.1159/000441073
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
In this study, we aim to examine the association of microRNA-586 (miR-586) with osteosarcoma (OS) cell proliferation, apoptosis, invasion, and metastasis. U2-OS cell lines were divided into 4 groups: an miR-586 group, anti-miR-586 group, control group (empty plasmid) and blank group (no plasmid). qRT-PCR was used to detect miR-586 expression, cell counting kit-8 and EdU assays to detect cell proliferation, flow cytometry to detect cell cycle distribution, Annexin V/PI double staining to detect cell apoptosis, and the Transwell assay to detect cell invasion and metastasis. miR-586 expression was significantly higher in the miR-586 group but significantly lower in the anti-miR-586 group compared with the control and blank groups. Cell proliferation at 2-5 days after cell transfection and the EdU-positive cell number increased obviously in the miR-586 group but decreased clearly in the anti-miR-586 group. In the miR-586 group, cells at G0/G1 stage and apoptosis cells significantly decreased, while cells at G2/M and S stages and invasive and metastatic cells significantly increased compared to the control and blank groups; however, opposite trends were found in the anti-miR-586 group. Downregulation of miR-586 expression in OS may inhibit cell proliferation, invasion and metastasis, and promote cell apoptosis. (C) 2015 S. Karger AG, Basel
引用
收藏
页码:268 / 278
页数:11
相关论文
共 31 条
  • [21] Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration
    Shimbo, Keisuke
    Miyaki, Shigeru
    Ishitobi, Hiroyuki
    Kato, Yoshio
    Kubo, Tadahiko
    Shimose, Shoji
    Ochi, Mitsuo
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 445 (02) : 381 - 387
  • [22] miR-218 expression in osteosarcoma tissues and its effect on cell growth in osteosarcoma cells
    Wang, Hong-Tai
    Liu, Ai-Gang
    Luo, Dao-Shu
    Zhou, Zhang-Nan
    Lin, Hong-Guang
    Chen, Rong-Zi
    He, Jin-Shui
    Chen, Kun
    [J]. ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2014, 7 (12) : 1000 - 1004
  • [23] Polymeric immunoglobulin receptor expression is correlated with poor prognosis in patients with osteosarcoma
    Wang, Xuanwei
    Du, Jingyu
    Gu, Pengcheng
    Jin, Rilong
    Lin, Xiangjin
    [J]. MOLECULAR MEDICINE REPORTS, 2014, 9 (06) : 2105 - 2110
  • [24] [魏任雄 WEI Ren-xiong], 2009, [中华实验外科杂志, Chinese Journal of Experimental Surgery], V26, P636
  • [25] MicroRNA-34a Inhibits Human Osteosarcoma Proliferation by Downregulating Ether a go-go 1 Expression
    Wu, Xinyu
    Zhong, Daixing
    Gao, Quan
    Zhai, Wenliang
    Ding, Zhenqi
    Wu, Jin
    [J]. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2013, 10 (06): : 676 - 682
  • [26] MiR-223/Ect2/p21 signaling regulates osteosarcoma cell cycle progression and proliferation
    Xu, Jianli
    Yao, Qi
    Hou, Yu
    Xu, Meng
    Liu, Sheng
    Yang, Longqiu
    Zhang, Lei
    Xu, Hui
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2013, 67 (05) : 381 - 386
  • [27] MicroRNA-9 expression is a prognostic biomarker in patients with osteosarcoma
    Xu, Shi-hong
    Yang, Yong-liang
    Han, Shu-mei
    Wu, Zong-hui
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2014, 12
  • [28] Zhang C, 2014, INT J CLIN EXP PATHO, V7, P4194
  • [29] Zhang ZY, 2013, EUR REV MED PHARMACO, V17, P767
  • [30] Zhao FY, 2015, INT J CLIN EXP PATHO, V8, P1451